Click here to read the latest top ASX cannabis stocks article.

The Australian cannabis market is offering investors a healthy dose of investment opportunities as the industry continues to expand in the country.


While the overall marijuana capital space has faced its fair share of volatility, which has affected Australian players as well, the emergent status of the sector in the country offers high upside in the long term for cannabis names attached to the Australian Securities Exchange (ASX).

Read along to find out about the top ASX cannabis stocks of 2019. All stock information and numbers were accurate as of December 16, 2019.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

1. Ecofibre (ASX:EOF)

Year-to-date gain: 51.18 percent; current share price: AU$2.57

First on the list of top ASX cannabis stocks is Ecofibre, a biotech company that is working on the development of hemp-derived items for human and pet consumption in the US and Australia. Its hemp offerings include products for the health and wellness markets.

In 2019, the company completed a variety of developments that are critical to its production pipeline. One of the biggest announcements for the company this year was its approval to the NASDAQ International Designation program. Thanks to this admission, the company has gained more access to US investors with over-the-counter options.

Ecofibre CEO Eric Wang said that since the company’s profile in the US is increasing, the international designation gives investors an easier way to follow its activities.

2. Althea Group Holdings (ASX:AGH)

Year-to-date gain: 29.63 percent; current share price: AU$0.35

Althea Group Holdings takes the concept of medical cannabis a step further with its work as a pharmaceutical-grade cannabis supplier. In addition to offering relief through accessible medical cannabis, the company is implementing components of the plant in the research for advanced drugs.

The company has steadily increased its reach across Australia, with its patient count nearing 4,000 at the end of 2019. Patients who are counted are those who have been prescribed Althea products.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

During an annual general meeting, Althea CEO Joshua Fegan told investors that the company holds enough capital to fund its future endeavors.

“Our goals for next year include reaching 10,000 patients in Australia, adding new products to our portfolio like we have just done with Althea CBD100 and continuing our expansion into the UK and Germany,” Fegan said.

3. Botanix Pharmaceuticals (ASX:BOT)

Year-to-date gain: 28.57 percent; current share price: AU$0.09

This pharmaceutical company has a focus on product development for dermatological conditions and offers treatments for acne, psoriasis, atopic dermatitis and other skin conditions in patients.

One of the company’s candidates, BTX 1503, progressed towards preparations for a Phase 3 clinical trial during 2019, which is a critical landmark.

The company received a boost for its business in the US after the US Drug Enforcement Administration told Purisys, a partner of Botanix, that synthetic cannabidiol (CBD) is not a controlled substance.

“This change in the regulation of synthetic CBD in the US will make a major difference to the speed of developing Botanic products and greatly reduces the risks and costs of clinical development,” Vince Ippolito, executive chairman and president of Botanix, said in a statement.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less